Literature DB >> 18716120

MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function.

Azusa Ichinose1, Hiroki Otani, Minako Oikawa, Kei Takase, Haruo Saito, Hiroaki Shimokawa, Shoki Takahashi.   

Abstract

OBJECTIVE: The objective of our study was to use MRI to analyze the topographic localization of myocardial lesions and their relationship to plasma brain natriuretic peptide (BNP) levels and several cardiac function parameters in patients with cardiac sarcoidosis.
MATERIALS AND METHODS: Delayed contrast-enhanced MRI was performed in 40 patients with sarcoidosis (11 cardiac, 29 extracardiac cases). Using a 29-segment model of the left ventricle (LV), the extent of myocardial hyperenhancement was visually scored (0 = no hyperenhancement, 1 = 1-25%, 2 = 26-50%, 3 = 51-75%, 4 = 76-100% hyperenhancement) and was compared with plasma BNP level and several parameters of cardiac function.
RESULTS: Ten of the 11 patients with cardiac sarcoidosis showed myocardial hyperenhancement, whereas none of the 29 patients without cardiac sarcoidosis did. In patients with cardiac sarcoidosis, hyperenhancement was significantly more extensive in basal short axis slices than in apical short axis slices (p < 0.0005). Myocardial hyperenhancement was significantly more frequent in subepicardial layers than in subendocardial layers. The global extent of myocardial hyperenhancement was significantly correlated with plasma BNP levels and the LV end-diastolic volume index and was negatively correlated with the LV ejection fraction.
CONCLUSION: In patients with cardiac sarcoidosis, myocardial lesions detected on delayed contrast-enhanced MRI were predominantly localized in the basal and subepicardial myocardium. The extent of myocardial lesions may be related to LV dysfunction and plasma BNP level in patients with cardiac sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18716120     DOI: 10.2214/AJR.07.3089

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  24 in total

1.  Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: The potential role of occult inflammation in arrhythmogenesis.

Authors:  Roderick Tung; Brenton Bauer; Heinrich Schelbert; Joseph P Lynch; Martin Auerbach; Pawan Gupta; Christiaan Schiepers; Samantha Chan; Julie Ferris; Martin Barrio; Olujimi Ajijola; Jason Bradfield; Kalyanam Shivkumar
Journal:  Heart Rhythm       Date:  2015-08-10       Impact factor: 6.343

Review 2.  Role of cardiac MRI in the assessment of nonischemic cardiomyopathies.

Authors:  Mahwash Kassi; Faisal Nabi
Journal:  Methodist Debakey Cardiovasc J       Date:  2013 Jul-Sep

Review 3.  Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis.

Authors:  Hiroshi Satoh; Makoto Sano; Kenichiro Suwa; Takeji Saitoh; Mamoru Nobuhara; Masao Saotome; Tsuyoshi Urushida; Hideki Katoh; Hideharu Hayashi
Journal:  World J Cardiol       Date:  2014-07-26

4.  Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging.

Authors:  Paco E Bravo; Ganesh Raghu; David G Rosenthal; Shana Elman; Bradley J Petek; Laurie A Soine; Jeffrey H Maki; Kelley R Branch; Sofia C Masri; Kristen K Patton; James H Caldwell; Eric V Krieger
Journal:  Int J Cardiol       Date:  2017-03-10       Impact factor: 4.164

5.  [Clinical indications for the use of cardiac MRI. By the SIRM Study Group on Cardiac Imaging].

Authors:  E Di Cesare; F Cademartiri; I Carbone; A Carriero; M Centonze; F De Cobelli; R De Rosa; P Di Renzi; A Esposito; R Faletti; R Fattori; M Francone; A Giovagnoni; L La Grutta; G Ligabue; L Lovato; R Marano; M Midiri; A Romagnoli; V Russo; F Sardanelli; L Natale; J Bogaert; A De Roos
Journal:  Radiol Med       Date:  2012-11-26       Impact factor: 3.469

6.  Investigation of cardiomyopathy using cardiac magnetic resonance imaging part 1: Common phenotypes.

Authors:  Shaunagh McDermott; Ailbhe C O'Neill; Carole A Ridge; Jonathan D Dodd
Journal:  World J Cardiol       Date:  2012-04-26

Review 7.  Pathophysiology and clinical management of cardiac sarcoidosis.

Authors:  Nabeel Hamzeh; David A Steckman; William H Sauer; Marc A Judson
Journal:  Nat Rev Cardiol       Date:  2015-02-24       Impact factor: 32.419

Review 8.  [Many faces of sarcoidosis].

Authors:  H Prosch; K Vonbank; C Loewe; D Beitzke
Journal:  Radiologe       Date:  2016-01       Impact factor: 0.635

Review 9.  Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment.

Authors:  Joseph P Lynch; Jennifer Hwang; Jason Bradfield; Michael Fishbein; Kalyanam Shivkumar; Roderick Tung
Journal:  Semin Respir Crit Care Med       Date:  2014-07-09       Impact factor: 3.119

10.  Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis.

Authors:  Tomas Vita; David R Okada; Mahdi Veillet-Chowdhury; Paco E Bravo; Erin Mullins; Edward Hulten; Mukta Agrawal; Rachna Madan; Viviany R Taqueti; Michael Steigner; Hicham Skali; Raymond Y Kwong; Garrick C Stewart; Sharmila Dorbala; Marcelo F Di Carli; Ron Blankstein
Journal:  Circ Cardiovasc Imaging       Date:  2018-01       Impact factor: 7.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.